ABSTRACT

INTRODUCTION. Pain syndrome in the back and large joints is the most frequent complaint at outpatient appointments. Osteoarthritis is one of the most common chronic musculoskeletal diseases worldwide, being the leading cause of chronic pain and disability. One of the possible causes of the development of musculoskeletal low back pain is degenerative changes of the intervertebral disc and osteoarthritis of the facet joints. The pathogenesis of facet syndrome is based on the imbalance between anabolic and catabolic processes within hyaline cartilage and subchondral bone. Therapy of patients with diseases of the musculoskeletal system should be carried out in a complex and include at all stages: diet, weight control, optimal motor regime, long-term use of SYSADOA (Symptomatic Slow Acting Drugs for OsteoArtritis) and pharmaconutraceuticals. ln some cases, the use of orthopaedic devices (orthoses, insoles) is indicated.

CONCLUSION. An integrated approach allows improving the quality of life and delaying the need for surgical interventions and the need for endoprosthesis. Of the SYSADOA available on the Russian market, chondroitin sulphate (Chondroguard®) has great evidence. lt is also promising to further study the efficacy of a new pharmaconutraceutical Chondroguard® TRlO, which was developed taking into account scientifically substantiated studies on the use of chondroitin sulfate, glucosamine sulfate and non-denatured type ll collagen and. This is optimal for nutritional support of patients with diseases of the musculoskeletal system. The presented algorithm allows optimising the diagnostic and therapeutic algorithm for patients with joint and back pain.

KEYWORDS: algorithm, back pain, osteoarthritis, chondroitin sulphate, pharmaconutraceuticals Chondroguard, Chondroguard TRlO

For citation: Shavlovskaya O.A. Algorithm for Managing Patients with Pain Syndrome. Comorbidity Neurology. 2024; 1 (4): 20-24. https://doi.org/10.62505/3034-185x-2024-1-4-20-24

For correspondence: Olga A. Shavlovskaya, Dr. Sci. (Med.), Professor, Chair of Organization of Medical Rehabilitation and Sanatorium Treatment, International University of Restorative Medicine, Moscow, Russia, e-mail: shavlovskaya@1msmu.ru

REFERENCES

1.Davydov O.S. Facet joint osteoarthritis as a component of non-specific low back pain. Neurology, Neuropsychiatry, Psychosomatics. 2019; 11 (Прил. 2): 76-82. https://doi.org/10.14412/2074-2711-2019-2S-76-82 (In Russ.)

2.Клинические рекомендации Минздрава России. Скелетно-мышечные (неспецифические) боли в нижней части спины. 2023. https://cr.minzdrav.gov.ru/recomend/778_1 

3.Alekseeva L.I., Barantsevich E.R., Vasilkin A.K. et al. Resolution of the consensus of Russian Federation experts on the diagnosis and treatment of osteoarthritis for primary care physicians. Therapy. 2022; 8 (5): 119-128. https://doi.org/10.18565/therapy.2022.5.119-128 (In Russ.)

4. Danilov A.B., Lila A.M., Majidova Yo.N. et al. New pharmaconutraceutical Chondroguard®TRIO for the prevention of musculoskeletal diseases and nutritional support for patients with osteoarthritis and nonspecific back pain: an assessment of clinical options. Resolution of the Multidisciplinary Expert Council. Neurology, Neuropsychiatry, Psychosomatics. 2023; 15 (2): 134-146. https://doi.org/10.14412/2074-2711-2023-2-134-146 (In Russ.)

5.Shavlovskaya O.A., Yukhnovskaya Yu.D., Romanov I.D., Bokova I.A. Pharmaconutraceutical Chondroguard®TRIO – chondroprotector with immunomodulatory activity. Neurology, Neuropsychiatry, Psychosomatics. 2023;15 (4): 105-111 https://doi.org/10.14412/2074-2711-2023-4-105-111. (In Russ.)

6. Kloppenburg M., Kroon .F, Blanco F., et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019; 78 (1): 16-24. https://doi.org/10.1136/annrheumdis-2018-213826

7.Bruyere O., Honvo G., Veronese N., et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49 (3): 337-50. https://doi.org/10.1016/j.semarthrit.2019.04.008

8.[Torshin I.Yu., Lila A.M., Naumov A.V., et al. Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (4): 388-399. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.066 (In Russ.)

9.Minasov T.B., Lila A.M., Nazarenko A.G., et al. Morphological reflection of highly purified chondroitin sulfate action in patients with decompensated form of knee osteoarthritis. Modern Rheumatology Journal. 2022; 16 (6): 55-63. https://doi.org/10.14412/1996-7012-2022-6-55-63 (In Russ.)

10.Minasov T.B., Lila A.M., Nazarenko A.G., et al. Stratification of decompensated osteoarthritis and modern options of the preoperative therapy using Chondroguard® based on pheno- and endotyping. Russian Medical Inquiry. 2023; 7(3): 124–136 https://doi.org/10.32364/2587-6821-2023-7-3-124-136 (In Russ.)

11.Клинические рекомендации Минздрава России. Падения у пациентов пожилого и старческого возраста. 2020. https://cr.minzdrav.gov.ru/recomend/600_1 

12.Клинические рекомендации Минздрава России. Хроническая боль у пациентов пожилого и старческого возраста. 2020. https://cr.minzdrav.gov.ru/recomend/616_1 

13.Клинические рекомендации Минздрава России. Гонартроз. 2021. https://cr.minzdrav.gov.ru/recomend/667_1

14.Клинические рекомендации Минздрава России. Коксартроз. 2021. https://cr.minzdrav.gov.ru/recomend/666_1

15.Shiojima Y., Takahashi M., Takahashi R., et al. Efficacy and safety of dietary undenatured type II collagen on joint and motor function in healthy volunteers: a randomized, double-blind, placebo-controlled, parallel-group study. J Am Nutr Assoc. 2022; 12 (7): 1-18. https://doi.org/10.1080/07315724.2021.2024466

16.Shavlovskaya O.A., Gromova О.А., Kochish A.Yu. et al. Disease-modifying osteoarthritis drugs (DMOADs): new trends in osteoarthritis therapy. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16 (3): 482-499. https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.207 (In Russ.)

17.Gencoglu H., Orhan C., Sahin E., Sahin K. Undenatured type II collagen (UC-II) in joint health and disease: a review on the current knowledge of companion animals. Animals. 2020;10: 697.  https://doi.org/10.3390/ani10040697  

18.Gromova O.A., Torshin I.Yu., Lila A.M., Shavlovskaya O.A. On the prospects for the use of undenatured type II collagen in the treatment of osteoarthritis and other joint diseases. Modern Rheumatology Journal. 2022; 16 (4):111-116. https://doi.org/10.14412/1996-7012-2022-4-111-116 (In Russ.)

19.Alekseeva L.I., Barulin A.E., Bakhtadze M.A., et al. Place and role of disease-modifying therapy and adjuvant support in complex therapy of chronic non-specific low back pain. Resolution of the Multidisciplinary Board of Experts. Journal of Pain. 2024; 22 (3): 110-118. https://doi.org/10.17116/pain202422031110 (In Russ.)

20.Shavlovskaya O.A., Gromova O.A., Torshin I.Yu. Points of undenatured type II collagen application in musculoskeletal pain syndromes treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2022; 122 (11): 40-45. https://doi.org/10.17116/jnevro202212211140 (In Russ.)

ADDITIONAL INFORMATION

Olga A. Shavlovskaya, Dr. Sci. (Med.), Professor, Chair of Organization of Medical Rehabilitation and Sanatorium Treatment, University of Restorative Medicine, Moscow, Russia. E-mail: shavlovskaya@1msmu.ru. ORCID: https://orcid.org/0000-0003-3726-0730

Author contributions. Author confirms their authorship according to the ICMJE criteria (author contributed significantly to the conception, study design and preparation of the article, read and approved the final version before publication). Shavlovskaya O.A. – concept and design, collection and processing of data from literature sources, statistical analysis of data from literature sources, text writing.

Funding. This study was  not supported by any external sources of funding.

Disclosure. Author declares no apparent or potential conflicts of interest related to the publication of this article.

The content is available under the Creative Commons Attribution 4.0 License.

©2024. Olga A. Shavlovskaya